<code id='1D2B6E4D2B'></code><style id='1D2B6E4D2B'></style>
    • <acronym id='1D2B6E4D2B'></acronym>
      <center id='1D2B6E4D2B'><center id='1D2B6E4D2B'><tfoot id='1D2B6E4D2B'></tfoot></center><abbr id='1D2B6E4D2B'><dir id='1D2B6E4D2B'><tfoot id='1D2B6E4D2B'></tfoot><noframes id='1D2B6E4D2B'>

    • <optgroup id='1D2B6E4D2B'><strike id='1D2B6E4D2B'><sup id='1D2B6E4D2B'></sup></strike><code id='1D2B6E4D2B'></code></optgroup>
        1. <b id='1D2B6E4D2B'><label id='1D2B6E4D2B'><select id='1D2B6E4D2B'><dt id='1D2B6E4D2B'><span id='1D2B6E4D2B'></span></dt></select></label></b><u id='1D2B6E4D2B'></u>
          <i id='1D2B6E4D2B'><strike id='1D2B6E4D2B'><tt id='1D2B6E4D2B'><pre id='1D2B6E4D2B'></pre></tt></strike></i>

          fashion

          fashion

          author:focus    Page View:13131
          Sammy Kimball for STAT

          Can biotech startups survive a downturn? Is Covid-19 a good business? And when did ophthalmology get so dramatic?

          We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. First, we discuss what some recent layoffs and a reverse merger mean for biotech in 2023. We’ll also discuss the latest news in the life sciences, including a dramatic saga in ocular medicine, the volatile business of Covid-19, and some major milestones in gene therapy.

          advertisement

          For more on what we cover, here’s the news on Celsius Therapeutics; here’s more on EQRx; here’s the latest on Apellis Pharmaceuticals; here’s where you can find episodes of Color Code; and here’s where you can subscribe to the First Opinion Podcast.

          Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

          And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

          explore

          As demand for Covid shots wanes, Moderna seeks its next success
          As demand for Covid shots wanes, Moderna seeks its next success

          RubyWallauforSTATModernachairmanNoubarAfeyanexudedstarpowerearlierthismonthashecommandedthespotlight

          read more
          Duchenne drug from Nippon Shinyaku fails in rare confirmatory trial
          Duchenne drug from Nippon Shinyaku fails in rare confirmatory trial

          Duchennemusculardystrophyhistopathology.Dr.EdwinP.Ewing,Jr./CDCJapanesedrugmakerNipponShinyakusaidon

          read more
          Moonlake's readout produced a cash windfall. Risks remain
          Moonlake's readout produced a cash windfall. Risks remain

          MollyFerguson/STATFortwodaysstartingonSunday,MoonlakeImmunotherapeuticshappilycrunchednumbersandshar

          read more

          AstraZeneca lung cancer study comes in below expectations

          LONDON—AstraZenecasaidonMondaythatanewlungcancertreatmentoutperformedstandard-of-carechemotherapyina